Wire flash
Haisco's HSK42360-Na tablet included in China's Breakthrough Therapy Drug List
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 27, Haisco Pharmaceutical announced that its self-developed drug HSK42360-Na tablet has been included in China's Breakthrough Therapy Drug List. HSK42360-Na is a BRAF paradoxical breaker inhibitor with excellent central nervous system penetration. Clinical trials show it has outstanding efficacy against BRAF V600-mutant high-grade glioma with a controllable safety profile. The project was also included in the 'Children's Anti-Tumor Drug Development Encouragement Pilot Program' in April 2026, and in June 2026, Haisco entered into a licensing agreement with US-based Nuvectis Pharma, granting exclusive global development, manufacturing, and commercialization rights outside Greater China. For the first half of 2026, Haisco reported revenue of 3.096 billion yuan and net profit attributable to shareholders of 851 million yuan. The article is sourced from Caizhongshe.
Source report
On September 27, Haisco Pharmaceutical (海思科) announced that HSK42360-Na tablets, a self-developed BRAF paradoxical breaker inhibitor, have demonstrated promising clinical results.
The drug features excellent central nervous system penetration. Clinical trials have shown significant efficacy against high-grade gliomas with BRAF V600 mutations, along with a manageable safety profile.
In addition, the project was included in the Pilot Program for Encouraging the Development of Pediatric Anti-Tumor Drugs in April 2026. In June 2026, Haisco entered into a licensing agreement with Nuvectis Pharma (USA), granting the company exclusive global rights—excluding Greater China—for the development, production, and commercialization of the drug.
In mid-2026, Haisco reported revenue of RMB 3.096 billion and net profit attributable to shareholders of RMB 851 million.
(Source: China Securities Journal)
Source
东方财富网-公司资讯Eastern